Sat.May 18, 2024 - Fri.May 24, 2024

article thumbnail

Why Healthcare Data Is Vital for Employers

MedCity News

Employers need healthcare data in order to make decisions, but the data isn’t always easy to get, experts said on a panel at MedCity INVEST. The post Why Healthcare Data Is Vital for Employers appeared first on MedCity News.

article thumbnail

At long last, AstraZeneca, Pfizer, J&J, Roche and others have an ally in Biden

Fierce Pharma

Over the last four years, with President Joe Biden milking a popular cause as an opponent of Big Pharma drug pricing, the industry has rarely seen good news coming from the White House. | Over the last four years, with President Joe Biden milking a popular cause as an opponent of Big Pharma's pricing, the industry has rarely seen good news coming from the White House.

Pharma 331
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Introducing the Clarivate Academic AI Platform

Clarivate

We have released the first version of the Clarivate Academic AI Platform, serving our suite of AI-powered Research Assistants. Discover how it is going to help address the needs of students, researchers and librarians for trusted AI. At Clarivate TM , we understand the transformative power of artificial intelligence (AI) in the academic realm and the imperative to introduce AI thoughtfully and responsibly into research, teaching and learning environments.

article thumbnail

Final report says UK infected blood scandal “should have been avoided”  

Pharmaceutical Technology

Nearly 30,000 people, including children in clinical trials, were infected with hepatitis C and HIV from contaminated blood products in the 1970s and 1980s.

130
130
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

5 Things to Know About the Sorry State of Healthcare Cybersecurity

MedCity News

During a fireside chat at MedCity News’ INVEST conference, Nitin Natarajan — deputy director at the Cybersecurity and Infrastructure Security Agency (CISA) — shared some key ideas that people need to understand about the current state of cybersecurity in the healthcare industry. For instance, he reminded us that things won’t get better overnight, and that cybersecurity requires an all-hands-on deck approach.

article thumbnail

Latest Ozempic results 'move the needle' for treating patients with diabetes, chronic kidney disease: Novo exec

Fierce Pharma

While it’s hard to overstate the success Novo Nordisk’s GLP-1 franchise has already achieved, the company’s latest deep dive into semaglutide data in chronic kidney disease (CKD) could help set a n | Early Friday, Novo shared full, positive results from the FLOW trial assessing the ability of once-weekly semaglutide 1.0 mg to help combat major kidney outcomes such as kidney failure, loss of kidney function and death from kidney or cardiovascular causes in people with Type 2 diabetes and chronic

Patients 322

More Trending

article thumbnail

FOCUS ON: Connected TV

PM360

PM360’s Focus On section examines a specific area of the life sciences industry. In this issue, we take a closer look at the evolution of the Smart TV and the increase of streaming services and how they can benefit the pharma industry. From connecting with patients by interactive ads to dabbling into cross-platform integration, here is what our specialists had to say.

Media 105
article thumbnail

Why Allegheny Health Network Created Its Own Chat-GPT For Employees

MedCity News

Allegheny Health Network rolled out a large language model designed exclusively for use by its staff members. You can think of the tool as the health system’s own version of Chat-GPT, said Ashis Barad, AHN’s chief digital and information officer. The post Why Allegheny Health Network Created Its Own Chat-GPT For Employees appeared first on MedCity News.

article thumbnail

Pfizer, busy with $4B savings drive, plots even more cuts out to 2027

Fierce Pharma

Pfizer has made frequent headlines in recent months as it moves forward with a campaign to save $4 billion in annual costs by the end of this year. | Pfizer has made frequent headlines in recent months as it moves forward with a campaign to save $4 billion in annual costs by the end of this year. Now, the company has unveiled another savings drive that will run longer.

317
317
article thumbnail

GSK’s twice-yearly asthma drug clears two phase 3 trials

pharmaphorum

GSK’s follow-up to its severe asthma therapy Nucala has shown its value in a pair of phase 3 trials, reducing exacerbations compared to placebo with dosing once every six months. The company says new IL-5 inhibitor depemokimab (formerly GSK3511294) has the potential to become the first ultra-long-acting biologic for severe asthma with a six-monthly dosing schedule.

104
104
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Biogen Agrees to Acquire HI-BIO for $1.15 Billion

Pharmaceutical Commerce

The deal features felzartamab, an investigational anti-CD38 monoclonal antibody, whose clinical outcomes have shown potential to tackle various immune-mediated diseases.

105
105
article thumbnail

The Powerful Hospice Lessons of Jimmy Carter  

MedCity News

Carter entered hospice care in his home, more than a year ago, and has set an inspirational example of how to live your last days on Earth with hope, meaning, and vigor. The post The Powerful Hospice Lessons of Jimmy Carter appeared first on MedCity News.

124
124
article thumbnail

Even after sharp sales drop, Pfizer sees bright side with priority review voucher from Paxlovid approval

Fierce Pharma

In a change of pace from the recent COVID-related business struggles for Pfizer, the drugmaker has picked up a valuable reward from the FDA in the form of a priority review voucher (PRV). | The FDA awarded the voucher based on Paxlovid's status as a countermeasure to a material medical threat, according to a notice in the Federal Register.

FDA 309
article thumbnail

Tony Blair Institute weighs in on use of NHS patient data

pharmaphorum

A think tank set up by former UK Prime Minister Tony Blair has called for the formation of a public-private trust that could oversee the sharing of anonymised patient data with trusted researchers.

Patients 103
article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

Researchers combine herpes virus with cancer vaccine to treat brain cancer in children

PharmaTimes

High-grade gliomas are rare, malignant tumours which account for up to 12% of all childhood brain tumours

127
127
article thumbnail

5 Things to Know About How NIH’s SEED Can Help Life Science Startups Grow

MedCity News

The NIH’s SEED office formed to help startups leverage government’s funding programs. Chris Sasiela, director of the SEED office, discussed these programs during the MedCity News INVEST Conference in Chicago. The post 5 Things to Know About How NIH’s SEED Can Help Life Science Startups Grow appeared first on MedCity News.

Biopharma 115
article thumbnail

Pfizer unit wins $107.5M verdict in cancer-drug patent case against AstraZeneca

Fierce Pharma

A Delaware federal jury has ordered AstraZeneca to fork over $107.5 million to Pfizer for infringing two of the latter company's patents with its marketing of blockbuster oncology med Tagrisso. | Pfizer's Wyeth subsidiary and licensee Puma Biotechnology sued AstraZeneca in 2021 for alleged patent infringement related to AZ's marketing of cancer blockbuster Tagrisso.

Marketing 315
article thumbnail

FDA competition seeks digital endpoints for Parkinson’s

pharmaphorum

FDA is asking artificial intelligence teams to develop a digital endpoint tool to study freezing of gait, a symptom of Parkinson’s that can have a serious impact on patients.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

AstraZeneca and Nona Biosciences sign agreement for monoclonal antibody

Pharmaceutical Technology

AstraZeneca has entered into a worldwide licence and option agreement with Nona Biosciences for a preclinical monoclonal antibody.

115
115
article thumbnail

Tax Challenges for Healthcare Accounting Teams Bring Opportunity for Innovation

MedCity News

A good outsourced partner can work alongside in-house accountants and stay on top of the moving target of healthcare accounting regulations, addressing tax risks and identifying cost-saving opportunities. The post Tax Challenges for Healthcare Accounting Teams Bring Opportunity for Innovation appeared first on MedCity News.

article thumbnail

ASCO: Bristol Myers unveils I-O triplet data in melanoma as Iovance touts ‘paradigm-changing’ combo result

Fierce Pharma

Over the years, melanoma has become a popular testing ground for researchers to explore new immuno-oncology approaches. | With prior approvals in melanoma, Bristol Myers Squibb and Iovance are now showcasing early clinical data for their novel combinations in small first-line melanoma trials.

306
306
article thumbnail

ASCO: AffyImmune claims a first with CAR-T for solid tumours

pharmaphorum

AffyImmune Therapeutics has recorded what it says is the first documented complete response in a patient with a solid tumour treated with CAR-T therapy. The case comes from a phase 1 study of its ICAM-1 targeting CAR-T autologous candidate AIC100 in patients with relapsed/refractory poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC), which will be reported at the ASCO congress next week.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

The Power of Grip: A Journey from Adversity to Success in the Consumer Goods Industry

Scott Burrows

In the world of motivational speaking, stories of triumph over adversity are not uncommon. But for me, the narrative goes beyond inspiration—it’s about embodying the very principles of vision, mindset, and grit that have shaped my journey. At the age of 19, a car accident left me with a broken neck and a daunting diagnosis of quadriplegia. But from the confines of a wheelchair, I refused to let my circumstances define me.

article thumbnail

Is the Healthcare Industry Embracing Risk in Its Contracts?

MedCity News

As the healthcare industry slowly moves toward value-based care, healthcare companies are thinking about taking on risk. During a panel at MedCity News’ INVEST conference, healthcare leaders shared some key ideas about how the industry is embracing risk in its contracts. The post Is the Healthcare Industry Embracing Risk in Its Contracts? appeared first on MedCity News.

article thumbnail

As Stelara nears patent cliff, J&J fortifies Tremfya for upcoming ulcerative colitis showdown

Fierce Pharma

The biologics market for inflammatory bowel disease is continually getting more competitive, and now Johnson & Johnson’s Tremfya is the latest medicine angling to make a mark in the space. | The biologics market for inflammatory bowel disease is continually getting more competitive, and now Johnson & Johnson’s Tremfya is the latest medicine angling to make a mark in the space.

article thumbnail

AstraZeneca sets lofty target of $80bn in revenues by 2030

pharmaphorum

AstraZeneca CEO Pascal Soriot says group revenues can reach $80bn by 2030, fuelled by a pipeline that features 'many' potential $5bn-plus candidates.

107
107
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Bristol Myers Squibb Plans 10-Year Strategy to Expand Access to Medications

PharmaTech

The company is collaborating with the Access to Oncology Medicines Coalition to expand patient access to immuno-oncology therapy Opdivo.

Medical 111
article thumbnail

‘The Time Is Now’: How Employers Can Offer Comprehensive Obesity Care

MedCity News

Employers are in a unique position to drive change in obesity care, but face several challenges. Experts shared numerous strategies employers can implement. The post ‘The Time Is Now’: How Employers Can Offer Comprehensive Obesity Care appeared first on MedCity News.

article thumbnail

Otsuka pulls plug on Alzheimer's agitation drug after 2nd failed trial

Fierce Pharma

Otsuka Pharmaceutical is packing up an Alzheimer’s disease med after a phase 3 study failed to move the needle on m | Otsuka Pharmaceutical is packing up an Alzheimer’s disease med after a phase 3 study failed to move the needle on measures of agitation associated with dementia.

article thumbnail

Novavax investor withdraws proxy fight after Sanofi deal

pharmaphorum

Shah Capital Management has withdrawn a proxy campaign against the re-election of director at vaccines firm Novavax in the wake of its $1.2 billion alliance with Sanofi. The top-three investor in Novavax – which has been steadily raising its stake in the company in recent weeks and now holds around 7.9% – said it welcomed the Sanofi deal but warned that “does not mean our engagement is at an end” and it still believes Novavax would benefit from a stockholder on its board of directors.

article thumbnail

ABM Evolution: How Top Marketers Are Using Account-Based Strategies

In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.